The research looked promising. The definitive trial was negative. Here's what the evidence actually shows — and what it means for your family.
Oxytocin — sometimes called the "love hormone" — has been one of the most studied potential treatments for autism-related social difficulties. The idea was straightforward: if oxytocin promotes social bonding, and some studies reported lower oxytocin levels in autistic individuals, could supplementing it improve social functioning?
Early small studies suggested it might. But the largest and most rigorous trial to date — published in the New England Journal of Medicine in 2021 — found no significant benefit of intranasal oxytocin over placebo for social or cognitive functioning in autistic children and adolescents over 24 weeks.
A 2024 dose-response meta-analysis found no consistent beneficial effects overall. NICE explicitly advises against using oxytocin for core autism features in adults. Research continues, but oxytocin is not established as an effective autism treatment.
Oxytocin is a hormone produced naturally in the brain (by the hypothalamus) and released by the pituitary gland. It plays a well-established role in:
In everyday terms, oxytocin is part of the biological system that makes social connection feel rewarding. It is not unique to humans — it plays a similar role across mammals.
The hypothesis came from several converging observations:
This was a biologically reasonable hypothesis backed by multiple lines of evidence. It attracted significant research funding and generated genuine scientific excitement.
The largest trial was published in the New England Journal of Medicine (Sikich et al., 2021). It was a multicentre, randomised, double-blind, placebo-controlled trial involving 290 children and adolescents (aged 3–17) with autism. Participants received intranasal oxytocin or placebo twice daily for 24 weeks.
Result: No significant difference between oxytocin and placebo on any measure of social or cognitive functioning.
The primary outcome (change in social functioning on the ABC-mSW scale) showed no between-group difference. Neither did any secondary outcomes, including the Social Responsiveness Scale, Clinical Global Impression, or Vineland Adaptive Behavior Scale.
This is the highest-quality evidence available, and it was unambiguously negative.
An Australian parallel randomised controlled trial of intranasal oxytocin in young children (3–12 years) with autism. Also found no significant benefit on the primary outcome measure of social interaction.
A Japanese RCT of 106 autistic men found some improvement in clinical global impression but no significant difference on the primary outcome (social reciprocity on the ADOS).
Earlier, smaller studies had reported encouraging signals:
These findings were real but based on single-dose studies or short-term trials with small samples. They did not translate into clinical benefit when tested properly at scale.
A comprehensive meta-analysis (Frontiers in Psychiatry, 2024) analysed all available RCTs. Key conclusions:
Several explanations have been proposed:
A 2025 review in the Journal of Psychopharmacology (Ricchiuti et al.) argued that the field needs to move beyond simple "give oxytocin and measure behaviour" designs toward more targeted approaches — identifying who might respond, optimising delivery, and combining oxytocin with behavioural interventions.
Yes. The oxytocin-autism research programme has not been abandoned. Several directions are being explored:
The research is not over, but the current evidence does not support clinical use.
NICE does not include oxytocin in its autism recommendations.
Overall: oxytocin is not an established autism treatment, is not routine care at any age, and is explicitly advised against for adults. Intranasal oxytocin is not licensed for autism in the UK.
Oxytocin nasal sprays and supplements are available from online retailers. Oxytocin products available online are not regulated as medicines, and should not be used to treat autism in children. There is no guarantee of their purity, dose accuracy, or safety.
If you are considering oxytocin for your child, speak to their paediatrician. Self-administering an unregulated hormone to a child based on internet marketing is not safe.
Oxytocin for autism is one of the most thoroughly investigated hypotheses in the field. The biological rationale was strong. The early signals were encouraging. But when tested in a large, well-designed NEJM trial, it did not improve social or cognitive functioning.
This is a similar story to bumetanide — a promising idea that did not survive the test of a definitive trial. The research continues, particularly around subgroup identification and delivery optimisation, but families should not pursue oxytocin as an autism treatment on the basis of current evidence.
Science progresses by testing ideas rigorously and accepting the results — even when they are disappointing. That is what happened here.
Looking at other research in this area? See our related guides:
Pitocin is synthetic oxytocin used intravenously to induce or augment labour. Intranasal oxytocin (used in autism research) is a different formulation delivered through the nose. They contain the same hormone but are used very differently.
Placebo effects are powerful, especially in autism interventions where parents are actively observing behaviour. Natural developmental progress can also be misattributed to a treatment. Single-dose studies did show real short-term effects (improved eye contact), which may reinforce the perception that it works — even though these effects did not translate into sustained clinical benefit.
This is an active area of research. Some scientists believe oxytocin may benefit individuals with the lowest baseline levels, or those with specific genetic profiles. But no reliable way to identify these individuals currently exists, and no subgroup analysis from the major trials has shown clear benefit.
No. Research continues into delivery methods, dosing, subgroup identification and combination approaches. But the current clinical evidence does not support using oxytocin as an autism treatment.
Disclaimer: SENDPath provides information for families navigating SEND in Kent and beyond. We are not clinicians. Nothing on this page constitutes medical advice. Always consult a qualified healthcare professional before making treatment decisions for your child. Read our full disclaimer.
Another promising hypothesis that didn't survive the definitive trial. A frank look at what the evidence shows for bumetanide.
Read guide →Early research, the FRAA hypothesis, what the trials found, and what families need to know.
Read guide →Cochrane review, TIME-A trial, and what the evidence says about music therapy for autism.
Read guide →The peripheral nerve research, what UK guidance says, and practical support for families.
Read guide →